Affimed’s AFM13 Data Show Potential Of NK Cell Approach
Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.
You may also be interested in...
An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.
iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.
Beware the hype but a deal with one of the big oncology players that involves $96m upfront and potentially $5.0bn in milestones is a decent validation for the German biotech's technology platform.